Form 4: BridgeBio Pharma CEO Neil Kumar Reports Stock Transactions
SEC Form 4 Filing
Neil Kumar, CEO of BridgeBio Pharma, reports the acquisition and disposal of common stock and restricted stock units, including transactions to cover tax obligations and sales under a pre-arranged Rule 10b5-1 plan.
Summary
- On February 16, 2025, Neil Kumar, the CEO of BridgeBio Pharma, acquired 55,539 shares of common stock through the vesting of Restricted Stock Units (RSUs).
- On the same day, 23,996 shares were withheld by the issuer to cover Kumar's tax obligations related to the RSU vesting.
- On February 19, 2025, Kumar sold 31,467 shares at a weighted average price of $36.1409 per share and 76 shares at $36.56 per share under a Rule 10b5-1 sales plan.
- Following these transactions, Kumar directly owns 211,718 shares of common stock.
- Kumar also indirectly owns 5,098,447 shares through the Kumar Haldea Revocable Trust and 995,686 shares through the Kumar Haldea Family Irrevocable Trust, where he serves as a co-trustee.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions by the CEO. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about insider trading activity.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. These filings are closely watched by investors for signals about management's confidence in the company's prospects.
Stakeholder Impact
- Shareholders may be interested in the CEO's stock transactions as an indicator of management's view of the company's value.
- The transactions themselves have a minimal impact on other stakeholders.
Key Dates
| Date | Description |
|---|---|
| 03/22/2024 | Rule 10b5-1 sales plan adopted by the Reporting Person |
| 02/16/2025 | Acquisition of 55,539 shares through RSU vesting. |
| 02/16/2025 | Withholding of 23,996 shares for tax obligations. |
| 02/19/2025 | Sale of 31,467 shares at a weighted average price of $36.1409 per share. |
| 02/19/2025 | Sale of 76 shares at $36.56 per share. |
Keywords
Form 4, BridgeBio Pharma, Neil Kumar, Stock Transactions, Restricted Stock Units, Rule 10b5-1, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.